Chemotherapy and pembrolizumab have been approved for the treatment of women with metastatic, recurring, or persistent cervical cancer whose tumours express PD-L1. Chemotherapy can be administered with or without bevacizumab. Whether pembrolizumab in this combination provides patients with a
Researchers have uncovered a gene that is overexpressed in mutated IDH1. Studies in human cells and a novel mouse model both show that this gene, called ZMYND8, plays a critical role in radiation resistance. When they knocked down the gene, the glioma cells became responsive to radiation tre
Researchers revealed that Immunotherapies have improved the outcomes of many cancer patients, including those with melanoma. However, only a subset of patients benefit from these treatments.
Researchers have uncovered a series of molecular interactions that may be crucial in preventing the spread of cancer cells. There is currently no effective therapeutic strategy to stop metastasis, which is the main cause of death from solid malignant tumours.
According to the findings of a study led by UC San Francisco, the progression of a low-grade, slow-growing brain tumour to a deadly one can be delayed if neurosurgeons remove as much as possible soon after diagnosis.
The method, described in the study published journal 'Nature Biotechnology,' records gene activity patterns and the presence of key proteins in cells across tissue samples while retaining information about the cells' precise location. This allows for the creation of complex, data-rich "maps"
Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic option for patients with these types of tumors.
Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumours sensitive to a type of immunotherapy drug called a checkpoint inhibitor. This is according to a new study published in Cancer Immunology Research by researchers at
According to new research, mice with colorectal cancer who have tumours with high levels of ammonia have fewer T cells and are less responsive to immunotherapy. Ammonia, which is crucial for anti-tumor immunity, has been demonstrated to impede the proliferation and operation of T cells.